Table 3.
Pregnancy and infant outcomes.
| Newborn | OCR Infusion | Complications | Infants’ data | APGAR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Preconception (weeks) | During pregnancy (weeks) | Pregnancy complications | Infant complications | Mode of delivery | Gender | BW (g) | Gestation (weeks) | 1min | 5min | |
| NB1 | 18 | No | No | No | LSCS | M | 3185 | 38 | 9 | 9 |
| NB2 | 18 | 5 | No | Posterior tongue tie | SVD | M | 3452 | 39 | 9 | 9 |
| NB3 | 22 | 9 | No | No | LSCS | F | 3425 | 38 | NA | NA |
| NB4 | 2 | No | No | No | LSCS | M | 3620 | 40 | 9 | 9 |
| NB5 | 17 | No | No | No | LSCS | M | 3430 | 40 | 7 | 9 |
| NB6 | 11 | No | Breech presentation | Mild and transient respiratory distress at birth | LSCS | F | 3220 | 38 | 9 | 9 |
| NB7 | 24 | No | No | No | LSCS | M | 3608 | 40 | NA | NA |
| NB8 | 8 | No | Placental insufficiency, oligohydramnios, breech presentation | Hyaline membrane disease, neonatal sepsis, hypoglycaemia | LSCS | M | 3180 | 38 | 7 | 9 |
| NB9 | 21 | No † | No | No | SVD, Forceps | M | 3900 | 38 | 6 | 9 |
| NB10 | 18 | No | GDM, primary PPH | No | LSCS | M | 2620 | 38 | 9 | 9 |
| NB11 | No | 2¶ | No | No | LSCS | F | 2930 | 38 | 9 | 10 |
| NB12 | 13 | No | No | No | SVD | F | 4018 | 40 | 9 | 9 |
| NB13 | 0.4 | No | No | No | LSCS | F | 3150 | 38 | 9 | 9 |
Legend: w: weeks, BW: birth weight, M: male, F: female, SVD: spontaneous vaginal delivery, LSCS: lower segment Caesarean Section, GDM: gestational diabetes, PPH: postpartum haemorrhage, NTZ: natalizumab, NA: not available.
† Mother received Natalizumab infusions throughout pregnancy as a bridging therapy in view of B cells repopulation during early stage of pregnancy.
¶ Only received a single 300mg dose of IV ocrelizumab. Was due for a second 300mg dose of ocrelizumab but fell pregnant before the scheduled infusion.